相关实验视频
Updated: Jun 22, 2025

07:57
A High-Throughput Comet Assay Approach for Assessing Cellular DNA Damage
Published on: May 10, 2022
4.9K
优化T-PLL的药物组合:恢复DNA损伤和P53介导的亡反应
Jana von Jan1,2,3, Sanna Timonen4,5,6, Till Braun1,2,3
1Department I of Internal Medicine, Center for Integrated Oncology Aachen-Bonn-Cologne-Duesseldorf, University Hospital Cologne, University of Cologne, Cologne, Germany.
Blood
|June 28, 2024
概括
这项研究确定了有效的药物组合,包括cladribine和MDM2抑制剂,用于治疗T-prolymphocytic白血病 (T-PLL). 这些疗法在临床前模型中通过恢复P53功能和增强亡,显示出有希望的前临床模型,为T-PLL治疗提供了新的希望.
科学领域:
- 血液学 血液学 血液学
- 在瘤学瘤学.
- 分子生物学分子生物学
背景情况:
- 型多淋巴细胞白血病 (T-PLL) 是一种具有攻击性成熟的T细胞瘤,结果不佳,耐化疗.
- 目前的治疗方法,如阿莱姆图祖马布 (Alemtuzumab),只能提供暂时的反应,因此需要通过异构移植进行整合.
- 了解T-PLL病理生物学揭示了表观遗传学,DNA损伤反应,细胞周期调节和生存途径的漏洞.
研究的目的:
- 评估针对T-PLL的各种向药物和组合的临床前疗效.
- 调查P53通路在T-PLL对MDM2抑制反应中的作用.
- 确定T-PLL治疗反应的预测标志物.
主要方法:
- 单个药物和组合的体外和体内测试,包括基因素脱乙酶 (HDAC) 抑制剂,BCL2抑制剂,循环素依赖激酶 (CDK) 抑制剂,小鼠双分钟2 (MDM2) 抑制剂和细胞静止剂.
- 对20个T-PLL初级样本进行了测试,并对42个额外的病例进行了验证,以及同基因小鼠模型和患者衍生异基移植.
- 分析TP53突变状态和克拉迪宾敏感性与RRM2表达的相关性.
主要成果:
- 克拉迪宾,罗米德普辛 (HDAC 抑制剂),维尼托克拉克斯 (BCL2 抑制剂) 和伊达萨努特林 (MDM2 抑制剂) 作为单一药物和组合药物表现出显著的疗效.
- T-PLL细胞显示出较低的亡原始化,具有异质的BCL2依赖性;TP53野生型T-PLL对MDM2抑制反应良好,增强了P53激活.
- 抑制MDM2与克拉迪宾协同作用,促进P53激活并增加染色质对基因的可访问性.
结论:
- 针对表观遗传调节,BCL2和P53通路的药理学策略对T-PLL具有治疗潜力.
- 抑制MDM2可以恢复T-PLL中P53-介导的亡,特别是在与克拉迪宾等药物结合使用时.
- 这些发现为未来T-PLL临床试验设计中的患者和化合物选择提供了基础.
相关概念视频
DNA Damage can Stall the Cell Cycle
9.1K
In response to DNA damage, cells can pause the cell cycle to assess and repair the breaks. However, the cell must check the DNA at certain critical stages during the cell cycle. If the cell cycle pauses before DNA replication, the cells will contain twice the amount of DNA. On the other hand, if cells arrest after DNA replication but before mitosis, they will contain four times the normal amount of DNA. With a host of specialized proteins at their disposal,cells must use the right protein at...
9.1K
Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Abnormal Proliferation
4.5K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.5K
The Intrinsic Apoptotic Pathway
6.5K
Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
6.5K
Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K
Negative Regulator Molecules
35.3K
Positive regulators allow a cell to advance through cell cycle checkpoints. Negative regulators have an equally important role as they terminate a cell’s progression through the cell cycle—or pause it—until the cell meets specific criteria.
35.3K

